Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Compounds Essential to Human Function01:25

Compounds Essential to Human Function

10.1K
The human body is composed of cells that are fundamentally made up of several different molecules. These molecules are essential to carry out all physiological processes in the body and are broadly classified into organic and inorganic based on their chemical structures.
Inorganic Compounds Essential to Human Functioning
Inorganic compounds essential to human functioning include water, salts, acids, and bases. These compounds are inorganic, i.e., they do not have a carbon-hydrogen bond. Water...
10.1K
Essential Minerals for Bone Health01:31

Essential Minerals for Bone Health

6.2K
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
6.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

879
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
879
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.8K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.8K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.1K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.1K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.6K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of daily step counts with cognitive, clinical, and resting-state electroencephalographic measures in patients with cognitive decline due to Alzheimer's disease.

GeroScience·2026
Same author

Glymphatic clearance as revealed by diffusion tensor imaging along the perivascular space (DTI-ALPS) is associated with Alzheimer's disease neuropathology and periodic rsEEG alpha rhythms in mild cognitive impairment participants.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Abnormal periodic and aperiodic resting-state electroencephalographic markers in Lewy body and Alzheimer's diseases with cognitive decline.

GeroScience·2026
Same author

Gender differences in non-motor symptoms in Parkinson's disease: a multicenter longitudinal study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Effects of combined Mediterranean diet and physical activity intervention on the gut microbiome and disease progression in individuals with Parkinson's disease: study protocol for a multicenter, randomized controlled pilot study (PRIME study).

Frontiers in aging neuroscience·2026
Same author

Enriched resting-state EEG prediction of cognitive decline in prodromal Alzheimer's disease: a machine-learning approach.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 26, 2026

Formulating and Characterizing an Exosome-based Dopamine Carrier System
06:08

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Published on: April 4, 2022

3.6K

Are All Dopamine Agonists Essentially the Same?

Margherita Torti1,2, Daniele Bravi1,3, Laura Vacca1,4

  • 1IRCCS San Raffaele Pisana, Center for Parkinson Disease, Rome, Italy.

Drugs
|April 11, 2019
PubMed
Summary
This summary is machine-generated.

Dopamine agonists (DAs) are effective for Parkinson's disease, managing motor and non-motor symptoms. Choosing the right DA depends on patient factors to optimize benefits and minimize risks.

More Related Videos

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
14:21

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

18.8K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Related Experiment Videos

Last Updated: Jan 26, 2026

Formulating and Characterizing an Exosome-based Dopamine Carrier System
06:08

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Published on: April 4, 2022

3.6K
Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
14:21

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

18.8K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Dopamine agonists (DAs) are a key treatment for Parkinson's disease (PD).
  • They improve motor function and non-motor symptoms while reducing motor complications.
  • Individual patient characteristics necessitate tailored DA selection.

Purpose of the Study:

  • To review the role of dopamine receptors in brain pathways.
  • To discuss the pharmacological profiles of non-ergoline DAs.
  • To outline class-related adverse effects of DAs.

Main Methods:

  • Review of literature on dopamine receptor distribution and function.
  • Analysis of pharmacokinetic and pharmacodynamic properties of non-ergoline DAs.
  • Examination of post-marketing data on adverse effects.

Main Results:

  • Dopamine receptors play distinct roles in various dopaminergic pathways.
  • Non-ergoline DAs exhibit unique efficacy and safety profiles.
  • Understanding these profiles aids in optimizing the benefit/risk ratio for PD patients.

Conclusions:

  • Personalized selection of dopamine agonists is crucial for effective Parkinson's disease management.
  • Consideration of comorbidities, non-motor symptoms, and patient characteristics guides optimal DA choice.
  • This approach enhances patient management by maximizing therapeutic benefits and minimizing adverse events.